Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Dec 19

PMID 31847470

Citations 12

Authors

Naoki Hosen

Affiliations

Soon will be listed here.

Abstract

CD19 Chimeric antigen receptor (CAR) T cell therapy has been shown to be effective for B cell leukemia and lymphoma. Many researchers are now trying to develop CAR T cells for various types of cancer. For multiple myeloma (MM), B-cell maturation antigen (BCMA) has been recently proved to be a promising target. However, cure of MM is still difficult, and several other targets, for example immunoglobulin kappa chain, SLAM Family Member 7 (SLAMF7), or G-protein coupled receptor family C group 5 member D (GPRC5D), are being tested as targets for CAR T cells. We also reported that the activated integrin β7 can serve as a specific target for CAR T cells against MM, and are preparing a clinical trial. In this review, we summarized current status of CAR T cell therapy for MM and discussed about the future perspectives.

Citing Articles

[Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma].

Gao S, Mu J, Li X, Wang J, Cui R, Li J Zhonghua Xue Ye Xue Za Zhi. 2024; 45(4):378-382.

PMID: 38951066 PMC: 11168002. DOI: 10.3760/cma.j.issn.0253-2727.2023.01.001.

The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer.

Yan P, Lin X, Wu L, Xu L, Li F, Liu J Nat Commun. 2024; 15(1):5255.

PMID: 38898050 PMC: 11187071. DOI: 10.1038/s41467-024-49625-y.

Amyloidoma and Plasmacytoma Presented as a Solitary Lung Nodule in a Patient of Multiple Myeloma With AL-Amyloidosis: A Case Report and Review of Literature.

Yadav R, Sun L, Cheema A, Yadav V, Wang J J Investig Med High Impact Case Rep. 2023; 11:23247096231184768.

PMID: 37421149 PMC: 10331339. DOI: 10.1177/23247096231184768.

Combating challenges in CAR-T cells with engineering immunology.

Wang C, Ting Cheung S, Sugimura R Front Cell Dev Biol. 2022; 10:969020.

PMID: 36299480 PMC: 9589253. DOI: 10.3389/fcell.2022.969020.

Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease.

Li W, Liu M, Yuan T, Yan L, Cui R, Deng Q Hematol Oncol. 2021; 40(2):223-232.

PMID: 34942032 PMC: 9305928. DOI: 10.1002/hon.2958.

References

Kuhn N, Purdon T, van Leeuwen D, Lopez A, Curran K, Daniyan A . CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response. Cancer Cell. 2019; 35(3):473-488.e6. PMC: 6428219. DOI: 10.1016/j.ccell.2019.02.006. View

Alfei F, Kanev K, Hofmann M, Wu M, Ghoneim H, Roelli P . TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature. 2019; 571(7764):265-269. DOI: 10.1038/s41586-019-1326-9. View

Ying Z, Huang X, Xiang X, Liu Y, Kang X, Song Y . A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019; 25(6):947-953. PMC: 7518381. DOI: 10.1038/s41591-019-0421-7. View

Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I . Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015; 373(7):621-31. DOI: 10.1056/NEJMoa1505654. View

Bakkus M, Heirman C, Van Riet I, Van Camp B, Thielemans K . Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood. 1992; 80(9):2326-35. View

Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M . Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018; 24(6):739-748. DOI: 10.1038/s41591-018-0036-4. View

Maeda T, Nagano S, Ichise H, Kataoka K, Yamada D, Ogawa S . Regeneration of CD8αβ T Cells from T-cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity. Cancer Res. 2016; 76(23):6839-6850. DOI: 10.1158/0008-5472.CAN-16-1149. View

Scott A, Dundar F, Zumbo P, Chandran S, Klebanoff C, Shakiba M . TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019; 571(7764):270-274. PMC: 7698992. DOI: 10.1038/s41586-019-1324-y. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

10.

Ramos C, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O . Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest. 2016; 126(7):2588-96. PMC: 4922690. DOI: 10.1172/JCI86000. View

11.

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

12.

Chen J, Lopez-Moyado I, Seo H, Lio C, Hempleman L, Sekiya T . NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019; 567(7749):530-534. PMC: 6546093. DOI: 10.1038/s41586-019-0985-x. View

13.

Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S . Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy. Cell Stem Cell. 2018; 23(6):850-858.e4. DOI: 10.1016/j.stem.2018.10.005. View

14.

June C, Sadelain M . Chimeric Antigen Receptor Therapy. N Engl J Med. 2018; 379(1):64-73. PMC: 7433347. DOI: 10.1056/NEJMra1706169. View

15.

Pont M, Hill T, Cole G, Abbott J, Kelliher J, Salter A . γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019; 134(19):1585-1597. PMC: 6871311. DOI: 10.1182/blood.2019000050. View

16.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

17.

Kalos M, Levine B, Porter D, Katz S, Grupp S, Bagg A . T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011; 3(95):95ra73. PMC: 3393096. DOI: 10.1126/scitranslmed.3002842. View

18.

Giavridis T, van der Stegen S, Eyquem J, Hamieh M, Piersigilli A, Sadelain M . CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018; 24(6):731-738. PMC: 6410714. DOI: 10.1038/s41591-018-0041-7. View

19.

Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M . The activated conformation of integrin β is a novel multiple myeloma-specific target for CAR T cell therapy. Nat Med. 2017; 23(12):1436-1443. DOI: 10.1038/nm.4431. View

20.

Matsui W, Wang Q, Barber J, Brennan S, Smith B, Borrello I . Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008; 68(1):190-7. PMC: 2603142. DOI: 10.1158/0008-5472.CAN-07-3096. View